Gene expression profiling of mesoblastic nephroma and Wilms tumors - Comparison and clinical implications

Urology

Volumn 64, Issue 2, 2004, Pages 362-368

  Sugimura, Jun ^a,b   Yang, Ximing J ^c   Tretiakova, Maria S ^d   Takahashi, Masayuki ^a,e   Kort, Eric J ^a   Fulton, Barbara ^f   Fujioka, Tomoaki ^b   Vogelzang, Nicholas J ^d   Teh, Bin Tean ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f SPECTRUM HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); HOMEODOMAIN PROTEIN; SOMATOMEDIN B; THROMBOSPONDIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CASE REPORT; DISEASE MARKER; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; MESENCHYME; MESOBLASTIC NEPHROMA; MOLECULAR DYNAMICS; NEPHROBLASTOMA; NEWBORN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; UPREGULATION;

ANTIGENS, NEOPLASM; CELL TRANSFORMATION, NEOPLASTIC; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, COMPLEMENTARY; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT, NEWBORN; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; NEPHROMA, MESOBLASTIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; WILMS TUMOR;

EID: 4143070459     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.04.052     Document Type: Article

References (21)

1. Campagnola S., Fasoli L., Flessati P., et al. Congenital cystic mesoblastic nephroma. Urol Int. 61:1998;254-256
2. Bisceglia M., Carosi I., Vairo M., et al. Congenital mesoblastic nephroma report of a case with review of the most significant literature. Pathol Res Pract. 196:2000;199-204
3. Driss M., Mrad K., Sabourin J.C., et al. [Atypical mesoblastic nephroma histopathological entity or specific anatomoclinical form?]. Bull Cancer. 89:2002;725-728
4. Birch J.M., Breslow N. Epidemiologic features of Wilms tumor. Hematol Oncol Clin North Am. 9:1995;1157-1178
5. Takahashi M., Yang X.J., Lavery T.T., et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res. 62:2002;6598-6605
6. Loeb D.M., Hill D.A., Dome J.S. Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol. 24:2002;478-481
7. McCahon E., Sorensen P.H., Davis J.H., et al. Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol. 40:2003;288-292
8. Ramachandran C., Melnick S.J., Escalon E., et al. Cytogenetic and molecular characterization of a congenital mesoblastic nephroma. Pediatr Dev Pathol. 4:2001;402-411
9. Sharifah N.A., Yun K., McLay J. Insulin-like growth factor II gene expression by congenital mesoblastic nephroma. Diagn Mol Pathol. 4:1995;279-285
10. Tomlinson G.E., Argyle J.C., Velasco S., et al. Molecular characterization of congenital mesoblastic nephroma and its distinction from Wilms tumor. Cancer. 70:1992;2358-2361
11. Hegde P., Qi R., Abernathy K., et al. A concise guide to cDNA microarray analysis. Biotechniques. 29:2000;548-556
12. Eisen M.B., Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol. 303:1999;179-205
13. Eisen M.B., Spellman P.T., Brown P.O., et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:1998;14863-14868
14. Rhodes D.R., Miller J.C., Haab B.B., et al. CIT identification of differentially expressed clusters of genes from microarray data. Bioinformatics. 18:2002;205-206
15. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 344:2001;539-548
16. Takahashi M., Yang X.J., Sugimura J., et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 22:2003;6810-6818
17. Reik W., Constancia M., Dean W., et al. IGF2 imprinting in development and disease. Int J Dev Biol. 44:2000;145-150
18. Zemel S., Bartolomei M.S., Tilghman S.M. Physical linkage of two mammalian imprinted genes, H19 and insulin-like growth factor 2. Nat Genet. 2:1992;61-65
19. Kaffer C.R., Grinberg A., Pfeifer K. Regulatory mechanisms at the mouse Igf2/H19 locus. Mol Cell Biol. 21:2001;8189-8196
20. Jarvinen T.A., Tanner M., Rantanen V., et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 156:2000;839-847
21. Iino K., Sasano H., Yabuki N., et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms a possible marker of differentiation between adenomas and carcinomas. Mod Pathol. 10:1997;901-907